Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 309

Sort by

Sort Order Select

Journal Articles

High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial

Blood (2025) 146 (15): 1747–1758.

https://doi.org/10.1182/blood.2025028313

Published: 2025

Includes: Supplemental data

Journal Articles

Ultrasensitive detection of circulating multiple myeloma cells by next-generation flow after immunomagnetic enrichment

Blood (2025) 146 (8): 964–970.

https://doi.org/10.1182/blood.2025029234

Published: 2025

Includes: Supplemental data

Journal Articles

The JAK2 46/1 haplotype influences PD-L1 expression

Gonzalo Carreño-Tarragona, María Tiana, Raquel Rouco, Alejandra Leivas, Jesús Victorino, Roberto García-Vicente, Andrew J. Chase, Andrea Maidana, William J. Tapper, Rosa Ayala, Nicholas C. P. Cross, Joaquín Martínez-López, Miguel Manzanares

Blood (2025) 145 (19): 2196–2201.

https://doi.org/10.1182/blood.2023023787

Published: 2025

Includes: Supplemental data

Journal Articles

Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma

Blood (2024) 144 (23): 2432–2438.

https://doi.org/10.1182/blood.2024024995

Published: 2024

Includes: Supplemental data

Journal Articles

Real-World Evidence of First-Line Therapy in Non-Transplant Eligible Multiple Myeloma Patients: Insights from the Cimma Study

Maria-Victoria Mateos, Fernando Escalante, Natalia Marin Huarte, Angela Garcia Garcia-Porrero, Miguel Jesús Villanueva Forero, Rafael Rios Tamayo, Antonia Sampol Mayol, Eugenio Gimenez, Jose-Angel Hernandez Rivas, Savana Research Group, Joaquín Martínez-Lopez

Blood (2024) 144 (Supplement 1): 7878.

https://doi.org/10.1182/blood-2024-206018

Published: 2024

Journal Articles

Central Nervous System Disorders (CNSD) Following Hematopoietic Stem Cell Transplantation (HSCT): A Prospective Study from the Infectious Diseases Working Party (IDWP) and the Transplant Complications Working Party (TCWP), European Society of Blood and Marrow Transplantation (EBMT)

Blood (2024) 144 (Supplement 1): 3497.

https://doi.org/10.1182/blood-2024-194695

Published: 2024

Journal Articles

Prognostic Impact of Measurable Residual Disease Evaluated By Next Generation Flow and PET-CT in Clinical Practice at Fundación Santa Fe De Bogotá Hospital, Colombia

Blood (2024) 144 (Supplement 1): 1943.

https://doi.org/10.1182/blood-2024-210959

Published: 2024

Journal Articles

Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-up and Selected High-Risk Subgroup Analyses of the Linker-MM1 Study

Blood (2024) 144 (Supplement 1): 3369.

https://doi.org/10.1182/blood-2024-199733

Published: 2024

Journal Articles

Real World Evidence of Outcomes of Patients Treated with Talquetamab in a Heavily Pretreated Population with Multiple Myeloma with High Exposure to Prior BCMA Therapies- a Report from the IMWG Consortium

Murali Janakiram, Carlyn Rose Tan, Rakesh Popat, Joaquín Martínez Lopez, Efstathios Kastritis, Chris Lau, Wee-Joo Chng, Prashant Kapoor, Hira Mian, Susan Bal, Ajay K. Nooka, Andre De Menezes Silva Corraes, Magdalena Corona, Arnab Chowdhury, Yi Lin, Thomas G Martin, Amrita Y Krishnan

Blood (2024) 144 (Supplement 1): 3368.

https://doi.org/10.1182/blood-2024-211167

Published: 2024

Journal Articles

Minimal Residual Disease Measured after Treatment with Bispecifics in Relapsed Multiple Myeloma: Experience from an Academic Medical Center

Alberto Blanco, Ajai Chari, Thomas G Martin, Shagun Arora, Alfred Chung, Anupama Deepa Kumar, Nina Shah, Sandy W. Wong, Hiroyuki Takamatsu, Joaquin Martínez-López, Jeffrey Lee Wolf

Blood (2024) 144 (Supplement 1): 7020.

https://doi.org/10.1182/blood-2024-203768

Published: 2024

Journal Articles

Artificial Intelligence Models for Risk Stratification and Prognosis in AML-NOS

Álvaro López-Caro, Ana Mendoza, Miguel Gómez-Álvarez, Marta Hidalgo Soto, Adriana Oñós Clausell, Sandra Rodríguez San Antolín, David Bermejo-Peláez, Nuria Díez Navarro, David Brau Queralt, Maria Postigo Camps, Rafael Colmenares Gil, Maria Jesus Ledesma-Carbayo, María Linares, Julia Montoro, Celina Benavente Cuesta, Miguel Luengo-Oroz, Joaquin Martínez-López

Blood (2024) 144 (Supplement 1): 7509.

https://doi.org/10.1182/blood-2024-207555

Published: 2024

Journal Articles

Clinical Utility of Ctdna Detection By NGS for Diagnosis of CNS Lymphoma

Ana Jiménez Ubieto, Alejandro Martín-Muñoz, Ricardo Errazquin, Yanira Ruiz-Heredia, Laura Rufián, Margarita Rodríguez, Esther Parra, Tycho Baumann, Antonia Rodriguez Izquierdo, Maria Teresa Cedena Romero, Joaquin Martínez-López, Rosa Ayala, Inmaculada Rapado

Blood (2024) 144 (Supplement 1): 6227.

https://doi.org/10.1182/blood-2024-207390

Published: 2024

Journal Articles

Potential Utility of Ctdna to Detect False Positive PET/CT in the Evaluation of Lymphoma Response

Alejandro Martín-Muñoz, Ana Jiménez Ubieto, Yanira Ruiz-Heredia, Laura Rufián, Margarita Rodríguez, Tycho Baumann, Antonia Rodriguez Izquierdo, Maria Poza Santaella, Daniel Gil Alos, Pilar Sarandeses, Enrique Revilla, Gloria Figaredo, Ricardo Errazquin, Inmaculada Rapado, Rosa Ayala, Santiago Barrio, Joaquin Martínez-López

Blood (2024) 144 (Supplement 1): 6204.

https://doi.org/10.1182/blood-2024-206966

Published: 2024

Journal Articles

Delayed Neurotoxicity after CAR-T in Multiple Myeloma: Results from a Global IMWG Registry

Blood (2024) 144 (Supplement 1): 4758.

https://doi.org/10.1182/blood-2024-201783

Published: 2024

Journal Articles

Long-Term Follow-up of Real-World Teclistamab Therapy for Relapsed/Refractory Multiple Myeloma from the IMWG Immunotherapy Working Group Committee

Blood (2024) 144 (Supplement 1): 5166.

https://doi.org/10.1182/blood-2024-210518

Published: 2024

Journal Articles

Real-World Evidence of First-Line Therapy in Transplant Eligible Multiple Myeloma Patients: Insights from the Cimma Study

Blood (2024) 144 (Supplement 1): 5164.

https://doi.org/10.1182/blood-2024-205945

Published: 2024

Journal Articles

Observational, Retrospective and Multicenter Analysis of Spanish CML Group , in Patients with Chronic Myeloid Leukemia in Treatment-Free Remission after Discontinuation of Bosutinib

Gonzalo Maortua Langdon, Raquel De Paz, Pilar Giraldo, Blanca Xicoy, Joaquin Martinez Lopez, Guiomar Bautista Carrascosa, Jose Maria Alonso Alonso, Maria Soledad Noya Pereira, Magdalena Sierra Pacho, Raul Perez Lopez, Silvana Daniela Saavedra Gerosa, Valle Gomez G De Soria, Natalia De Las Heras, Valentín García Gutiérrez, Sr.

Blood (2024) 144 (Supplement 1): 6604.

https://doi.org/10.1182/blood-2024-208460

Published: 2024

Journal Articles

Retrospective Analysis of Spanish Real-World Data Investigating First Line Treatment Patterns in a Representative Sample of Chronic Lymphocytic Leukemia Patients

Zuzana Dostalova, Kai Strobel, Tycho Baumann, Fatima Miras, Joaquín Martínez-Lopez, José Antonio Garcia Vela, Stefan Schilling, Markus Rückert

Blood (2024) 144 (Supplement 1): 7804.

https://doi.org/10.1182/blood-2024-202047

Published: 2024

Journal Articles

CRISPR/Cas9 Multi-Editing Enhances CAR NK Cells Therapeutic Potential Against Multiple Myeloma

Blood (2024) 144 (Supplement 1): 3442.

https://doi.org/10.1182/blood-2024-207942

Published: 2024

Journal Articles

Clinical Outcomes of Patients with High-Risk Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 ELARA 4-Year Update

Blood (2024) 144 (Supplement 1): 3034.

https://doi.org/10.1182/blood-2024-201730

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial

Ultrasensitive detection of circulating multiple myeloma cells by next-generation flow after immunomagnetic enrichment

The JAK2 46/1 haplotype influences PD-L1 expression

Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma

Real-World Evidence of First-Line Therapy in Non-Transplant Eligible Multiple Myeloma Patients: Insights from the Cimma Study

Central Nervous System Disorders (CNSD) Following Hematopoietic Stem Cell Transplantation (HSCT): A Prospective Study from the Infectious Diseases Working Party (IDWP) and the Transplant Complications Working Party (TCWP), European Society of Blood and Marrow Transplantation (EBMT)

Prognostic Impact of Measurable Residual Disease Evaluated By Next Generation Flow and PET-CT in Clinical Practice at Fundación Santa Fe De Bogotá Hospital, Colombia

Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-up and Selected High-Risk Subgroup Analyses of the Linker-MM1 Study

Real World Evidence of Outcomes of Patients Treated with Talquetamab in a Heavily Pretreated Population with Multiple Myeloma with High Exposure to Prior BCMA Therapies- a Report from the IMWG Consortium

Minimal Residual Disease Measured after Treatment with Bispecifics in Relapsed Multiple Myeloma: Experience from an Academic Medical Center

Artificial Intelligence Models for Risk Stratification and Prognosis in AML-NOS

Clinical Utility of Ctdna Detection By NGS for Diagnosis of CNS Lymphoma

Potential Utility of Ctdna to Detect False Positive PET/CT in the Evaluation of Lymphoma Response

Delayed Neurotoxicity after CAR-T in Multiple Myeloma: Results from a Global IMWG Registry

Long-Term Follow-up of Real-World Teclistamab Therapy for Relapsed/Refractory Multiple Myeloma from the IMWG Immunotherapy Working Group Committee

Real-World Evidence of First-Line Therapy in Transplant Eligible Multiple Myeloma Patients: Insights from the Cimma Study

Observational, Retrospective and Multicenter Analysis of Spanish CML Group , in Patients with Chronic Myeloid Leukemia in Treatment-Free Remission after Discontinuation of Bosutinib

Retrospective Analysis of Spanish Real-World Data Investigating First Line Treatment Patterns in a Representative Sample of Chronic Lymphocytic Leukemia Patients

CRISPR/Cas9 Multi-Editing Enhances CAR NK Cells Therapeutic Potential Against Multiple Myeloma

Clinical Outcomes of Patients with High-Risk Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 ELARA 4-Year Update

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only